North America Autoinjectors Market By Type (Disposable autoinjectors and Reusable autoinjectors), By Application (Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications), By End Use (Hospitals & Clinics and Home care settings), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Autoinjectors Market
Market Report Description
The North America Autoinjectors Market would witness market growth of 16.9% CAGR during the forecast period (2020-2026). As per the US National Health Council, approximately 75% of the healthcare expenditure of the nation is used in the treatment of chronic diseases, including diabetes. The main share of expenditures is acquired by patients who are living with a chronic disorder is compelled by the regular need to get medicated, which may necessitate repeated visits to either hospitals or out-patient clinics.
With time, a range of solutions that enable self-administration of drugs has been developed and presented into the market. In a reasonably short time period, the market for self-injection devices has full-fledged into a conspicuous and promising segment in the pharmaceutical industry. Autoinjectors are one such device that has witnessed amplified adoption among patients, particularly for the treatment of emergency situations like anaphylactic shocks. As per the developers, these devices are quite easier to use as compared to parenteral drug delivery systems and have incorporated needle-safety features. It has been proved that the autoinjectors have resolved a number of issues faced by patients such as injection-related tolerability.
Market growth is mainly driven by the increasing incidences of targeted therapies, the increasing occurrence of anaphylaxis, growing inclination for self-administration of drugs. Further, the usability benefits, the growing number of governing approvals, and the accessibility of standard versions of autoinjectors, favorable settlements pertaining to the autoinjectors is fuelling the market. In addition, government’s provision as well as technological advancements are likely to turn this market more opportunistic. The patent termination of biologics is also anticipated to deliver growth opportunities for the market.
Based on Type, the market is segmented into Disposable autoinjectors and Reusable autoinjectors. Based on Application, the market is segmented into Anaphylaxis, Rheumatoid Arthritis, Multiple Sclerosis and other Applications. Based on End Use, the market is segmented into Hospitals & Clinics and Home care settings. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly and Company, GlaxoSmithKline PLC (GSK), Merck Group, Sanofi S.A., Becton, Dickinson and Company, Teva Pharmaceuticals Industries Ltd., Amgen, Inc., Ypsomed AG, AbbVie, Inc. and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Disposable autoinjectors
- Reusable autoinjectors
- Rheumatoid Arthritis
- Multiple Sclerosis
- Other Applications
By End Use
- Hospitals & Clinics
- Home care settings
- Rest of North America
- Eli Lilly and Company
- GlaxoSmithKline PLC (GSK)
- Merck Group
- Sanofi S.A.
- Becton, Dickinson and Company
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- Ypsomed AG
- AbbVie, Inc.
- Biogen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free